AM-Pharma is backed by a strong syndicate of international investors, including venture capital funds and corporate venture funds. To date, the company has raised over €190 million in equity and debt.
In March 2020, AM-Pharma increased its funding to €163 million to conduct its global Phase III REVIVAL pivotal trial of ilofotase alfa in sepsis-associated acute kidney injury. Additional funds of €47 million have been added to the initial €116 million that were raised from an international syndicate of investors. New investors joining existing investors are LSP, Andera, Cowen Healthcare.
In addition, the Dutch Ministry of Economic Affairs (Netherlands Enterprise Agency – RVO) granted AM-Pharma non-dilutive financing.